Memotal (Piracetam)

Piracetam, the active ingredient in Memotal, is a racetam (nootropic) presented as an injectable for intramuscular and intravenous use. It is prescribed to support cognitive function and neurological recovery in adults with identified impairments, including age‑related cognitive decline, post‑stroke deficits, myoclonus and dyslexia, aiming to enhance neuroplasticity and cerebral metabolism.

GNH USA supplies Memotal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memotal (piracetam) is employed in several neurological and cognitive disorder pathways to improve brain function.

Cognitive impairment: improves attention, memory and learning performance in affected individuals. Post‑stroke recovery: supports restoration of cognitive abilities after cerebral ischemic events. Myoclonus: reduces involuntary muscle jerks associated with cortical hyperexcitability. Dyslexia: may enhance reading and language processing in patients with developmental reading disorders.

Adverse reactions to Memotal are generally infrequent but may occur following intramuscular or intravenous administration.

Common Side Effects: - Injection site pain: mild discomfort at the site of administration. - Headache: transient headache reported by some patients. - Nausea: occasional feeling of nausea. - Dizziness: brief episodes of light‑headedness.

Serious or Rare Side Effects: - Allergic reaction: rash, itching, swelling, or anaphylaxis. - Seizure exacerbation: potential worsening of seizure activity in susceptible individuals. - Blood pressure changes: hypotension or hypertension. - Thrombotic events: rare clot formation at injection site.

When prescribing Memotal, clinicians should consider several precautionary measures to ensure safe use.

Renal impairment: adjust use and monitor renal function. Hepatic disease: evaluate liver status before administration. Elderly patients: start with lower doses and observe tolerance. Concurrent CNS stimulants: assess risk of increased excitability. Pregnancy and lactation: avoid unless benefits outweigh potential risks. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Memotal may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Anticoagulants: increased bleeding risk when combined with injectable piracetam. - Anticonvulsants: potential reduction of seizure control. - Monoamine oxidase inhibitors: risk of hypertensive episodes.

Moderate Interactions (Monitor Closely): - CNS depressants: additive sedation or dizziness. - Diuretics: possible electrolyte imbalance. - Beta‑blockers: may affect blood pressure response.